Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
S Idell, LEL Beckert, B Brockway, G Simpson, AM Southcott, YCG Lee, NM Rahman, RW Light, S Shoemaker, JD Gillies, AA Komissarov, G Florova, K Sarva
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | AMER THORACIC SOC | Published : 2019
Awarded by NIH SMARTT
Awarded by NIH
This abstract is funded by: Lung Therapeutics, Inc. (LTI), NIH SMARTT HHSN268201100014C(SI) and NIH UO-1 HL121841-01A1(SI).